These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25258254)

  • 1. Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system.
    Sasagawa Y; Akai T; Tachibana O; Iizuka H
    J Neurooncol; 2015 Jan; 121(1):177-83. PubMed ID: 25258254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal Fluid IL-10 and IL-10/IL-6 as Accurate Diagnostic Biomarkers for Primary Central Nervous System Large B-cell Lymphoma.
    Song Y; Zhang W; Zhang L; Wu W; Zhang Y; Han X; Yang C; Zhang L; Zhou D
    Sci Rep; 2016 Dec; 6():38671. PubMed ID: 27924864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological analysis and specific discriminating markers of interleukin detection in cerebrospinal fluid with primary central nervous system lymphoma: results from a retrospective study.
    Li J; Tang X; Luo X; Liu L; Li D; Yang L
    Ann Hematol; 2023 Aug; 102(8):2153-2163. PubMed ID: 37289220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients.
    Nguyen-Them L; Costopoulos M; Tanguy ML; Houillier C; Choquet S; Benanni H; Elias-Shamieh R; Armand M; Faivre G; Glaisner S; Malak S; Vargaftig J; Hoang-Xuan K; Ahle G; Touitou V; Cassoux N; Davi F; Merle-Béral H; Le Garff-Tavernier M; Soussain C;
    Eur J Cancer; 2016 Jul; 61():69-76. PubMed ID: 27156226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL).
    Sasayama T; Nakamizo S; Nishihara M; Kawamura A; Tanaka H; Mizukawa K; Miyake S; Taniguchi M; Hosoda K; Kohmura E
    Neuro Oncol; 2012 Mar; 14(3):368-80. PubMed ID: 22156547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CSF and clinical data are useful in differentiating CNS inflammatory demyelinating disease from CNS lymphoma.
    Ikeguchi R; Shimizu Y; Shimizu S; Kitagawa K
    Mult Scler; 2018 Aug; 24(9):1212-1223. PubMed ID: 28657431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-marker algorithms based on CXCL13, IL-10, sIL-2 receptor, and β2-microglobulin in cerebrospinal fluid to diagnose CNS lymphoma.
    Maeyama M; Sasayama T; Tanaka K; Nakamizo S; Tanaka H; Nishihara M; Fujita Y; Sekiguchi K; Kohta M; Mizukawa K; Hirose T; Itoh T; Kohmura E
    Cancer Med; 2020 Jun; 9(12):4114-4125. PubMed ID: 32314548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
    Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
    Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic and prognostic value of interleukin-10 in cerebrospinal fluid for central nervous system lymphoma: a meta-analysis.
    Wang L; Luo L; Gao Z; Liu SF; Liu CJ; Ma DX; Chen JG; Cao WR; Yin AM; Xu JW; Wang SL; Zhuo DJ; Geng B; Zhao SS; Wang FY; Yang N; Guan LX; Gu ZY; Gao CJ
    Leuk Lymphoma; 2017 Oct; 58(10):2452-2459. PubMed ID: 28278715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma.
    Mabray MC; Barajas RF; Villanueva-Meyer JE; Zhang CA; Valles FE; Rubenstein JL; Cha S
    AJNR Am J Neuroradiol; 2016 Jan; 37(1):74-9. PubMed ID: 26381553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.
    Baraniskin A; Kuhnhenn J; Schlegel U; Chan A; Deckert M; Gold R; Maghnouj A; Zöllner H; Reinacher-Schick A; Schmiegel W; Hahn SA; Schroers R
    Blood; 2011 Mar; 117(11):3140-6. PubMed ID: 21200023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-30c as a novel diagnostic biomarker for primary and secondary B-cell lymphoma of the CNS.
    Baraniskin A; Chomiak M; Ahle G; Gress T; Buchholz M; Turewicz M; Eisenacher M; Margold M; Schlegel U; Schmiegel W; Hahn S; Schroers R
    J Neurooncol; 2018 May; 137(3):463-468. PubMed ID: 29327175
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Zhou W; Wen J; Hua F; Xu W; Lu X; Yin B; Geng D; Guan Y
    Eur J Radiol; 2018 Jul; 104():26-32. PubMed ID: 29857862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new diagnostic marker for differentiating multicentric gliomas from multiple intracranial diffuse large B-cell lymphomas on 18F-FDG PET images.
    Wang K; Zhao X; Chen Q; Fan D; Qiao Z; Lin S; Jiang T; Dai J; Ai L
    Medicine (Baltimore); 2017 Aug; 96(32):e7756. PubMed ID: 28796066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in cerebrospinal fluid interleukin-10 levels display better performance in predicting disease relapse than conventional magnetic resonance imaging in primary central nervous system lymphoma.
    Zhang Y; Zou D; Yin J; Zhang L; Zhang X; Wang W; Zhang M; Zhou D; Zhang W
    BMC Cancer; 2021 Feb; 21(1):183. PubMed ID: 33618687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cerebrospinal fluid EBV-DNA and IL-10 as markers for in vivo diagnosis of AIDS-related primary central nervous system lymphoma.
    De Luca A; Antinori A; Cingolani A; Larocca LM; Linzalone A; Ammassari A; Scerrati M; Roselli R; Tamburrini E; Ortona L
    Br J Haematol; 1995 Aug; 90(4):844-9. PubMed ID: 7669663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers.
    Loser V; Segot A; de Leval L; Bisig B; Brouland JP; Hewer E; Barcena C; Hottinger AF; Pot C
    BMC Neurol; 2024 Jul; 24(1):250. PubMed ID: 39039441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic Value of sLR11 and sIL-2R in the Cerebrospinal Fluid for Malignant Central Nervous System Lymphoma.
    Shimizu N; Nakao S; Hasunuma H; Nakaseko C; Shimizu T; Ebinuma H; Bujo H
    Intern Med; 2024 Oct; 63(20):2767-2771. PubMed ID: 38432983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. STAT3 activation is associated with cerebrospinal fluid interleukin-10 (IL-10) in primary central nervous system diffuse large B cell lymphoma.
    Mizowaki T; Sasayama T; Tanaka K; Mizukawa K; Takata K; Nakamizo S; Tanaka H; Nagashima H; Nishihara M; Hirose T; Itoh T; Kohmura E
    J Neurooncol; 2015 Sep; 124(2):165-74. PubMed ID: 26080800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can metabolic tumor parameters on primary staging
    Okuyucu K; Alagoz E; Ince S; Ozaydin S; Arslan N
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):9-14. PubMed ID: 28733137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.